FDA Warns Teva Subsidiary Over Quality Failures, CGMP Violations

FDA Warns Teva Subsidiary Over Quality Failures, CGMP Violations

Source: 
RAPS.org
snippet: 

Teva Pharmaceuticals subsidiary Actavis Laboratories FL, Inc. received a warning letter last month from the US Food and Drug Administration (FDA) for quality unit concerns and inconsistencies with its laser-drilled tablet manufacturing processes, among other violations.